| 摘要 |
<P>PROBLEM TO BE SOLVED: To provide a pharmaceutical composition which is suitable for treating: a patient with type I and type II diabetes mellitus, prediabetes or reduced glucose tolerance, and further with rheumatoid arthritis, obesity, or calcitonin-induced osteoporosis; as well as a patient for which an allograft transplantation has been carried out. <P>SOLUTION: Polymorphic crystal modifications of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthine, their production and their use method for the preparation of a drug are provided. <P>COPYRIGHT: (C)2013,JPO&INPIT |
